文献速递儿科与产科急症重症综合管理与镇静镇痛

先天性心脏病术后新生儿的酮咯酸给药与结局:一项回顾性分析

Ketorolac Dosing and Outcomes in Neonates Following Congenital Heart Surgery: A Retrospective Analysis.
PubMed 文献 · Crit Care Explor · 2024-04-16
一句话结论单中心回顾性研究提示,新生儿心脏术后按0.5 mg/kg每6小时给予酮咯酸,肾脏功能与出血风险方面可能安全,但需前瞻性验证。

本研究为单中心回顾性队列研究,纳入2020年11月至2023年7月接受心脏手术后使用酮咯酸的39例新生儿(年龄<28天)。酮咯酸按机构临床管理算法给予0.5 mg/kg每6小时一次。主要安全性结局为临床显著肾功能下降(复合终点:酮咯酸启动后96小时内血清肌酐较基线升高≥0.3 mg/dL且尿量≤0.5 mL/kg/hr持续6小时);次要安全性结局为临床显著出血(复合国际血栓与止血学会儿童主要出血标准与Nellis等2019年严重/致命性出血标准)。结果显示无患者发生显著肾功能下降,无临床显著出血事件。阿片类药物用量中位数在启动酮咯酸时为0.2 MME/kg/d(IQR 0.1-0.25),启动后48小时为0.1 MME/kg/d(IQR 0.1-0.2)。作者认为若经前瞻性验证,该方案对肾功能和出血风险可能安全,但需随机研究确定其阿片节约效能。

要点

  • 单中心回顾性纳入39例心脏术后新生儿,酮咯酸中位剂量0.5 mg/kg/次,中位疗程48小时(IQR 6-48小时)。
  • 主要安全性终点(96小时内肌酐升高≥0.3 mg/dL且尿量≤0.5 mL/kg/hr持续6小时)发生率为0,无临床显著出血事件。
  • 阿片用量中位数从启动酮咯酸时的0.2 MME/kg/d(IQR 0.1-0.25)降至48小时的0.1 MME/kg/d(IQR 0.1-0.2)。
  • 作者认为该方案在肾功能和出血风险方面可能安全,但需前瞻性验证;阿片节约效能需随机研究确定。

适用人群与场景

  • 年龄<28天、接受心脏手术后使用酮咯酸的新生儿,研究期间为2020年11月至2023年7月(含首尾)。

诊断标准与关键阈值

  • 主要安全性终点:酮咯酸启动后96小时内血清肌酐较基线升高≥0.3 mg/dL,且尿量≤0.5 mL/kg/hr持续6小时,定义为临床显著肾功能下降。
  • 次要安全性终点:临床显著出血,定义为国际血栓与止血学会儿童主要出血标准与Nellis等(2019年)严重/致命性出血标准的复合终点。

处置流程与药物剂量

  • 酮咯酸按机构临床管理算法给予0.5 mg/kg每6小时一次,中位剂量0.5 mg/kg/次,中位疗程48小时(IQR 6-48小时)。
  • 镇痛效果通过标准化疼痛评分驱动的镇痛方案下阿片类药物用量评估。

研究设计与关键结果

  • 单中心回顾性队列研究,纳入39例符合标准的新生儿。
  • 无患者发生显著肾功能下降,无临床显著出血事件。
  • 阿片类药物用量中位数(IQR)在酮咯酸启动时为0.2 MME/kg/d(0.1-0.25 MME/kg/d),启动后48小时为0.1 MME/kg/d(0.1-0.2 MME/kg/d)。

证据类型、等级与局限

  • 证据类型:单中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,若经前瞻性验证,新生儿心脏术后按0.5 mg/kg/次每6小时给予酮咯酸的方案在肾功能和出血风险方面可能安全。
  • 作者指出,需开展随机研究以确定酮咯酸在阿片节约方面的效能。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pain management is essential for postoperative surgery. Given the association of opioids with adverse outcomes, interest in the use of nonopioid analgesics, such as ketorolac, has increased. Published data on use in neonates are limited.

OBJECTIVES: To describe ketorolac dosing and safety and efficacy outcomes in the first 48 hours postcardiac surgery in neonates.

DESIGN: We performed a single-center retrospective cohort study of neonates (ages < 28 d) who received ketorolac following cardiac surgery from November 2020 to July 2023 (inclusive). The primary safety outcome was a clinically significant decline in renal function, as defined by the composite of an increase in serum creatinine by greater than or equal to 0.3 mg/dL from baseline within 96 hours of ketorolac initiation and urine output less than or equal to 0.5 mL/kg/hr for 6 hours. The secondary safety outcome was clinically significant bleeding, defined as the composite of major bleeding by the International Society on Thrombosis and Hemostasis pediatric criteria and severe/fatal bleeding by the criteria of Nellis et al (2019). Efficacy was measured by opioid utilization based on a standardized pain score-driven analgesia protocol.

INTERVENTIONS: Ketorolac was administered at 0.5 mg/kg every 6 hours as per an institutional clinical management algorithm.

MEASUREMENTS AND MAIN RESULTS: Thirty-nine patients met the eligibility criteria. The median ketorolac dose was 0.5 mg/kg/dose, and median (interquartile range [IQR]) duration of therapy was 48 hours (6-48 hr). No patients experienced a significant decline in renal function, and there were no clinically significant bleeding events. The median (IQR) IV morphine milligram equivalents (MMEs)/kg/d of opioid administration was 0.2 MME/kg/d (0.1-0.25 MME/kg/d) at the time of ketorolac initiation and 0.1 MME/kg/d (0.1-0.2 MME/kg/d) at 48 hours post-ketorolac initiation.

CONCLUSIONS: If validated prospectively, these findings suggest that a ketorolac regimen of 0.5 mg/kg/dose every 6 hours in neonates postcardiac surgery may be safe with regard to renal function and bleeding risk. Additional randomized studies would be needed to determine efficacy with regard to opioid-sparing capacity.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Kiskaddon AL, Goldenberg NA, Abel T, et al. Ketorolac Dosing and Outcomes in Neonates Following Congenital Heart Surgery: A Retrospective Analysis. Crit Care Explor. 2024. PMID: 38633134. doi:10.1097/CCE.0000000000001078

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。